DPYSL3, dihydropyrimidinase like 3, 1809

N. diseases: 52; N. variants: 4
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach 		0.020 AlteredExpression disease BEFREE The combination of serum ANOS1 and DPYSL3 levels increased the AUC value that discriminated patients with GC from healthy controls. 31377880 2020
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma 		0.020 AlteredExpression disease BEFREE The combination of serum ANOS1 and DPYSL3 levels increased the AUC value that discriminated patients with GC from healthy controls. 31377880 2020
CUI: C1510586
Disease: Autism Spectrum Disorders
Autism Spectrum Disorders 		0.020 Biomarker disease BEFREE This review summarizes current knowledge regarding the role of CRMP4 during brain development and discusses the possible contribution of CRMP4 deficiencies or abnormalities to the pathogenesis of ASD. 31137494 2019
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.010 Biomarker disease BEFREE DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. 30498031 2018
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.010 Biomarker disease BEFREE DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. 30498031 2018
CUI: C3539878
Disease: Triple Negative Breast Neoplasms
Triple Negative Breast Neoplasms 		0.010 AlteredExpression disease BEFREE A Clinical Proteomic Tumor Analysis Consortium (CPTAC) proteogenomic analysis prioritized dihydropyrimidinase-like-3 (DPYSL3) as a multilevel (RNA/protein/phosphoprotein) expression outlier specific to the claudin-low (CLOW) subset of triple-negative breast cancers. 30498031 2018
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.100 AlteredExpression phenotype BEFREE Enhancing CRMP4 expression by promoter-targeted small activating RNAs reduced cell migration in vitro and abolished distal metastasis in mouse xenograft models. 30081723 2018
CUI: C0410702
Disease: Adolescent idiopathic scoliosis
Adolescent idiopathic scoliosis 		0.100 GeneticVariation disease GWASCAT The coexistence of copy number variations (CNVs) and single nucleotide polymorphisms (SNPs) at a locus can result in distorted calculations of the significance in associating SNPs to disease. 30019117 2018
CUI: C1837461
Disease: SCOLIOSIS, ISOLATED, SUSCEPTIBILITY TO, 3
SCOLIOSIS, ISOLATED, SUSCEPTIBILITY TO, 3 		0.100 GeneticVariation disease GWASCAT The coexistence of copy number variations (CNVs) and single nucleotide polymorphisms (SNPs) at a locus can result in distorted calculations of the significance in associating SNPs to disease. 30019117 2018
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.100 PosttranslationalModification phenotype BEFREE We then focused on the cooperative crosstalk of calpain-2 and NF-κB RelA/p65 in CRMP4 promoter methylation for the initiation of PCa metastasis. 29601651 2018
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.080 PosttranslationalModification disease BEFREE We then focused on the cooperative crosstalk of calpain-2 and NF-κB RelA/p65 in CRMP4 promoter methylation for the initiation of PCa metastasis. 29601651 2018
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.070 PosttranslationalModification disease BEFREE We then focused on the cooperative crosstalk of calpain-2 and NF-κB RelA/p65 in CRMP4 promoter methylation for the initiation of PCa metastasis. 29601651 2018
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.100 Biomarker phenotype BEFREE A metastatic lung tumor model in which the stable DPYSL3 knockdown LLC cells were injected through tail vein was used to analyze the role of DPYSL3 in tumor metastasis in vivo. 29514686 2018
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.080 Biomarker phenotype BEFREE Cell migration and invasion assays were performed to determine the role of DPYSL3 in LLC cells' migration and invasion changes. 29514686 2018
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm 		0.040 Biomarker group BEFREE A metastatic lung tumor model in which the stable DPYSL3 knockdown LLC cells were injected through tail vein was used to analyze the role of DPYSL3 in tumor metastasis in vivo. 29514686 2018
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.020 AlteredExpression disease BEFREE The correlation between DPYSL3 expression and the survival time of lung cancer patients were analyzed in KMPLOT database. 29514686 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.020 AlteredExpression disease BEFREE The correlation between DPYSL3 expression and the survival time of lung cancer patients were analyzed in KMPLOT database. 29514686 2018
CUI: C1306460
Disease: Primary malignant neoplasm of lung
Primary malignant neoplasm of lung 		0.020 AlteredExpression disease BEFREE The correlation between DPYSL3 expression and the survival time of lung cancer patients were analyzed in KMPLOT database. 29514686 2018
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms 		0.010 Biomarker group BEFREE A metastatic lung tumor model in which the stable DPYSL3 knockdown LLC cells were injected through tail vein was used to analyze the role of DPYSL3 in tumor metastasis in vivo. 29514686 2018
CUI: C0153676
Disease: Secondary malignant neoplasm of lung
Secondary malignant neoplasm of lung 		0.010 Biomarker disease BEFREE This study aimed to analyze the correlation between DPYSL3 and metastatic lung cancer. 29514686 2018
CUI: C0243038
Disease: Carcinoma, Lewis Lung
Carcinoma, Lewis Lung 		0.010 Biomarker disease BEFREE Stable DPYSL3 knockdown Lewis lung carcinoma (LLC) cells were constructed with a retroviral system. 29514686 2018
CUI: C0686619
Disease: Secondary malignant neoplasm of lymph node
Secondary malignant neoplasm of lymph node 		0.030 Biomarker disease BEFREE A previous result showed that collapsin response mediator protein 4 (CRMP4) promotor methylation can be used as a predictor for lymph node metastases in prostate biopsies. 29308052 2018
CUI: C0024299
Disease: Lymphoma
Lymphoma 		0.010 PosttranslationalModification group BEFREE Collapsin response mediator protein 4 promotor methylation level as a potential predictor for diagnosing primary malignant lymphoma of the prostate. 29308052 2018
CUI: C0862636
Disease: Adenocarcinoma of the prostate metastatic
Adenocarcinoma of the prostate metastatic 		0.010 PosttranslationalModification disease BEFREE The CRMP4 promotor methylation level in paraffin-embedded tissues of the 10 patients with PMLP were determined and then compared to limited prostate cancer (LPCa) and its negative lymph node tissue [LPCa-LN (-) (10 cases)] and also to metastatic prostate adenocarcinoma (mPCa) and its positive lymph node tissue [mPCa-LN (+) (10 cases)]. 29308052 2018
CUI: C1335512
Disease: Prostate Lymphoma
Prostate Lymphoma 		0.010 PosttranslationalModification disease BEFREE Collapsin response mediator protein 4 promotor methylation level as a potential predictor for diagnosing primary malignant lymphoma of the prostate. 29308052 2018